Taylor-CousarĮMERYVILLE, Calif., J(GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced positive interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis lung disease. Company to host live webcast today at 4:30 p.m.Dose selection and initiation of Phase 2 Dose Expansion stage expected in H2 2023 additional interim data including for cohort 2 participants (2E15 vg dose) expected at the North American Cystic Fibrosis Conference in November 2023.Bronchoscopy sample results demonstrated widespread and consistent expression of the cystic fibrosis transmembrane conductance regulator (CFTR) transgene protein in 92-99% of lung airway cells, at levels significantly above normal control lung tissues.Percent predicted forced expiratory volume in one second (ppFEV 1 ) meaningfully improved in participant with moderate ppFEV 1 impairment at baseline ppFEV 1 maintained stable in participants with normal or mild impairment at baseline. ![]() ![]() Quality of life outcomes measured by Cystic Fibrosis Questionnaire-Revised respiratory symptom score (CFQ-R-R) meaningfully improved for all three participants.Reported data from cohort 1 (n=3, 1E15 vg dose) of cystic fibrosis modulator treatment ineligible/intolerant participants with 9-12 months follow-up.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |